Fellow Seeking Alpha contributor Paul Nouri made a very solid call naming Trinity Biotech (NASDAQ:TRIB) a Top Idea back in late June, as the shares have risen about 60% since then. While I do like this under-followed Irish diagnostics specialist, I have to wonder if the stock has gone too far too fast. Even if I assume uncommonly high free cash flow margins and that the company captures one-third of the troponin and BNP testing markets, the numbers just don't work for me right now.
Building From A Solid Base
I'll get to the growth part of the Trinity story soon, but it's well worth noting that Trinity is no one-trick pony and has a strong base diagnostics...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|